Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose in 12-18 Months Old Healthy Children

Trial Profile

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose in 12-18 Months Old Healthy Children

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs GSK 2202083A (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Meningococcal vaccine group C conjugate; Pneumococcal 10-valent vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Acronyms DTPA-HBV-IPV=HIB-MENC-TT-004 BST: 002
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top